Clouds. 54.7   F New York
AI-Powered News Summarizer
Top Stories

Novavax coronavirus vaccine becomes fifth to begin Phase 3 trials in United States

December 28, 2020. Summarized by summa-bot.

Compression ratio: 58.9%. 1 min read.

Novavax on Monday announced the start of the Phase 3 trial of its Covid-19 vaccine in the United States and Mexico. It is the fifth company to launch a large-scale trial of a coronavirus vaccine in the United States.

(CNN)Novavax on Monday announced the start of the Phase 3 trial of its Covid-19 vaccine in the United States and Mexico.

It is the fifth company to launch a large-scale trial of a coronavirus vaccine in the United States.

The trial for the vaccine candidate, known as NVX-CoV2373, will evaluate safety, efficacy and immune response in up to 30,000 people age 18 and older.

It builds on Phase 1/2 studies that demonstrated that the vaccine provoked an immune response and appeared to be safe.

The trial is examining whether the vaccine prevents Covid-19 symptoms, as well as moderate or severe Covid-19 symptoms.

"With the COVID-19 pandemic raging around the globe, this trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world's population," Stanley C.

Novavax is also currently conducting a Phase 3 clinical study in the United Kingdom, a Phase 2b trial in South Africa and a Phase 1/2 continuation in the US and Australia, data from which are expected as soon as early first quarter 2021.

Both began Phase 3 trials in the US in July and enrolled over 30,000 participants.

AstraZeneca began the Phase 3 US trial of its coronavirus vaccine in September.

Johnson & Johnson, which is testing a single-dose vaccines, expects efficacy results from its Phase 3 trial by January or February.

Summarizer is on Google News. Now you can get the latest AI summarized news on your favorite news platform.

Don't like Google News? We have an RSS Feed for you.

Suggestions